Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
22.08.2013 22:58:00

Thoratec Presentation At Morgan Stanley 2013 Health Care Conference To Be Webcast

PLEASANTON, Calif., Aug. 22, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Morgan Stanley 2013 Health Care Conference on Monday, September 9.

Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 10:50 a.m., Pacific Daylight Time (1:50 p.m., Eastern Daylight Time).

The presentation will be available through the conference web site at http://cc.talkpoint.com/morg007/090913a_mc/?entity=104_CVDC2KU, or on the company's web site at http://www.thoratec.com.

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag® and PediMag®/PediVAS® product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web site at http://www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate, HeartMate II and GoGear are registered trademarks of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.

SOURCE Thoratec Corporation

Nachrichten zu Thoratec Corp.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Thoratec Corp.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!